UroGen Pharma Ltd
Ownership
Ownership Structure
Who owns UroGen Pharma Ltd (URGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 88.8% of the shares are freely tradable; institutional investors hold 100.6%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RTW INVESTMENTS, LLC | 9.30 | 4,543,895 | +0.0 | 06/30/2026 |
| BlackRock Inc | 6.55 | 3,201,461 | +12.5 | 06/30/2026 |
| Morgan Stanley - Brokerage Accounts | 5.27 | 2,576,363 | +0.6 | 06/30/2026 |
| Kynam Capital Management, LP | 4.98 | 2,434,207 | +8.3 | 06/30/2026 |
| Jefferies Financial Group Inc | 4.50 | 2,199,652 | +0.0 | 06/30/2026 |
| SG Americas Securities, LLC | 4.20 | 2,052,906 | +23.8 | 06/30/2026 |
| American Century Companies Inc | 3.45 | 1,685,719 | +2.9 | 06/30/2026 |
| Point72 Asset Management, L.P. | 3.12 | 1,525,549 | +0.0 | 06/30/2026 |
| Frontier Capital Management CO Inc | 3.09 | 1,508,547 | +14.8 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RTW Biotech Opportunities Ord | 3.80 | 1,858,445 | +36.8 | 12/31/2025 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Schoenberg Mark | Chief Medical Officer | 59,882 | 1,958,141 $ | Sep 8, 2026 | direct |
| Smith Jason Drew | General Counsel | 53,141 | 1,737,711 $ | Sep 8, 2026 | direct |
| Robinson James A. Jr. | Director | 8,000 | 261,600 $ | Aug 26, 2026 | direct |
| Degnan Chris | Chief Financial Officer | 4,561 | 149,145 $ | Oct 8, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 8, 2026 | Degnan Chris | Chief Financial Officer | Sell | 2,202 | 36.69 | 80,791 |
| Oct 8, 2026 | Degnan Chris | Chief Financial Officer | Other | 4,483 | – | – |
| Sep 8, 2026 | Schoenberg Mark | Chief Medical Officer | Sell | 871 | 42.92 | 37,383 |
| Sep 8, 2026 | Smith Jason Drew | General Counsel | Sell | 1,519 | 42.54 | 64,618 |
| Sep 7, 2026 | Schoenberg Mark | Chief Medical Officer | Other | 1,667 | – | – |
| Sep 7, 2026 | Smith Jason Drew | General Counsel | Other | 3,334 | – | – |
| Aug 26, 2026 | Robinson James A. Jr. | Director | Other | 2,000 | – | – |
| Aug 20, 2026 | Schoenberg Mark | Chief Medical Officer | Sell | 60,677 | 47.05 | 2,854,853 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.